ESC 365 - Effect of LOX-1 inhibition on coronary atherosclerosis among patients with residual inflammation after myocardial infarction

ESC2025 Premium Access

Effect of LOX-1 inhibition on coronary atherosclerosis among patients with residual inflammation after myocardial infarction

Session: Nature Medicine: 2025 highlights

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Speaker: Doctor M. O'Donoghue (Boston, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Michelle O'Donoghue

Brigham and Women's Hospital, Boston (United States of America)

9 presentations

6 followers

3 more presentations in this session

Phase 1 trial of a monoclonal antibody targeting the angiopoietin-like protein 3/8 complex in patients with mixed hyperlipidaemia

Speaker: Doctor D. Gaudet (Montreal, CA)

Effects of vutrisiran on echocardiographic measures of cardiac structure and function: the HELIOS-B trial

Speaker: Doctor K. Jering (Boston, US)

Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid-lowering

Speaker: Doctor N. Marston (Boston, US)

Access the full session

Nature Medicine: 2025 highlights

Speakers: Doctor M. O'Donoghue, Doctor D. Gaudet, Doctor K. Jering, Doctor N. Marston

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources